26 results
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
5 Jan 24
Results of Operations and Financial Condition
5:01pm
Technologies Serving Well - funded, High - growth Secular Markets Demographic Tailwinds 7 R&D $222B (2021)* NIH Grants $30.2B (2021)* R&D $60B (2021)* Estimated … R&D expenditure within HBIO markets US Federal $179B 2021 9.3% 2016 - 2021 Pre - clinical market $5B (2021) 5 7
Subset of blue - chip recurring
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
4 Aug 22
Harvard Bioscience Announces Second Quarter 2022 Financial Results
7:01am
due primarily to incremental investments in R&D and increased marketing expenses. Gross margin improved to 58% from 57%. On a GAAP basis, operating
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
4 May 22
Harvard Bioscience Announces First Quarter 2022 Financial Results
7:01am
costs associated with ongoing global supply disruptions. We also funded growth investments in R&D and marketing. On a GAAP basis, we recorded … in the year. However, we will continue incremental investments in R&D to sustain double-digit growth over the long run.”
Quarterly Financial Results
8-K
EX-99.1
fw54see5o
8 Mar 22
Harvard Bioscience Announces Fourth Quarter 2021 Financial Results
7:00am
8-K
EX-99.1
jmxw ry8wjtbbuh9t054
1 Oct 14
Expected to Add $7.5 Million to $8.5 Million in Revenue in 2015
12:00am